Impact of Training Status on Bioavailability of Flavanones
キーワード
概要
日付
最終確認済み: | 11/30/2015 |
最初に提出された: | 12/01/2015 |
提出された推定登録数: | 12/07/2015 |
最初の投稿: | 12/10/2015 |
最終更新が送信されました: | 12/07/2015 |
最終更新日: | 12/10/2015 |
実際の研究開始日: | 08/31/2013 |
一次完了予定日: | 07/31/2015 |
研究完了予定日: | 07/31/2015 |
状態または病気
介入/治療
Behavioral: Experimental tests
Behavioral: Experimental tests
段階
アームグループ
腕 | 介入/治療 |
---|---|
Experimental: Experimental tests 2 sets of experimental tests; once, during a period of normal training and repeated following one week of de-training | Behavioral: Experimental tests 5-10 hours of endurance training each week |
適格基準
研究の対象となる年齢 | 18 Years に 18 Years |
研究に適格な性別 | Male |
健康なボランティアを受け入れる | はい |
基準 | Inclusion Criteria: - trained regularly for at least 4 years and typically perform at least 5 hours of endurance training per week (distance runners, triathletes, cyclists) - healthy - normotensive - non-smokers - not taking any drug therapies - VO2 max >50 ml/kg body mass Exclusion Criteria: - history of gastrointestinal disease - vegetarian - unstable food habits - VO2 max < 50 ml/kg body mass |
結果
主な結果の測定
1. • Plasma pharmacokinetics of naringenin, hesperetin, eriodictyol, isorhamnetin and phenolic acid metabolites [24 hours]
2. • Urinary excretion of naringenin, hesperetin, eriodictyol, isorhamnetin and phenolic acid metabolites [24 hours]
二次的な結果の測定
1. Maximal Oxygen Consumption [30 minutes]
2. Body weight [7 days]
3. Body fatness [7 days]
4. Dietary Intake [7 days]